- ongoing, recruitingTherapeutic exploratory (Phase II)
INCB 39110-801 A Phase 2, Open-Label, Multicenter, Rollover Study to Provide Continued Treatment for Participants Previously Enrolled in Studies of Itacitinib (INCB039110)
This study offers ongoing treatment with a medicine called Itacitinib for adults who have already participated in earlier studies of this drug. It primarily monitors for any side effects and ensures continued access to the medication for conditions like myelofibrosis or chronic graft-versus-host disease.
Italy · Spain · Austria - recruitingPHASE3
A Long-term Extension Study of PCI-32765 (Ibrutinib)
This study offers ongoing access to a drug called ibrutinib for people already using it for certain blood cancers and conditions, who are still benefiting. It also helps gather more long-term information on how safe and effective ibrutinib is.
United States · Argentina · Australia - active not recruitingPHASE2
A Rollover Study to Provide Continued Treatment for Participants Previously Enrolled in Studies of Itacitinib
This study is for people already taking the drug itacitinib in other Incyte studies. It allows them to continue getting the treatment if it's helping and they are tolerating it well. It's for conditions like myelofibrosis, lung transplant problems, and chronic graft-versus-host disease.
United States · Austria · Belgium - recruitingPHASE2
A Study of Axatilimab at 3 Different Doses in Participants With Chronic Graft Versus Host Disease (cGVHD)
This study is testing a new medicine called axatilimab for chronic graft-versus-host disease (cGVHD) in people who haven't responded well to other treatments. It will see how well axatilimab works at three different dose levels and if it’s safe to use.
United States · Australia · Belgium - recruitingPHASE2
A Study to Evaluate Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft-Versus-Host Disease After at Least 2 Prior Lines of Systemic Therapy (AGAVE-256)
This study looks at a new medicine called Axatilimab for children aged 2-17 with a condition called chronic Graft-versus-Host Disease (cGVHD). These children have already tried at least two other treatments. The study compares Axatilimab with existing best treatments to see which works better.
United States · Belgium · Germany - recruitingPHASE3
A Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease
This study is looking at a new medicine called axatilimab, alongside standard steroids, for people with chronic graft-versus-host disease (cGVHD). It compares axatilimab with a dummy medicine (placebo) to see how well it works to treat this condition.
United States · Australia · Austria - active not recruitingPHASE2
A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease
This study looks at a new drug, axatilimab, combined with an existing one, ruxolitinib, to treat a condition called chronic graft-versus-host disease (cGVHD). It aims to see how safe and effective this new combination is.
United States · Belgium · Canada - recruitingPHASE2
A Study of Belumosudil in Children With Chronic Graft Versus Host Disease (schoolROCK)
This study is looking at a new medicine called Belumosudil for children aged 1 to 18 with chronic graft versus host disease (cGVHD). We want to see how well it works and if it's safe for those who haven't responded to other treatments.
United States · Belgium · Canada - active not recruitingPHASE3
A Study to Evaluate Axatilimab Versus Best Available Therapy in Participants With Chronic Graft Versus Host Disease After at Least 2 Prior Lines of Systemic Therapy
This study is testing a new medicine, axatilimab, for people in the UK aged 12 and over with chronic graft-versus-host-disease (cGVHD) that hasn't improved with other treatments. It compares axatilimab to other standard therapies to see if it works better.
Austria · Belgium · Czechia - active not recruitingPHASE3
A Study to Test an Oral Medicine, Belumosudil, in Combination With Corticosteroids in Participants at Least 12 Years of Age With Newly Diagnosed Chronic Graft Versus Host Disease.
This study is testing a new medicine, Belumosudil, alongside standard steroids for people aged 12 and over newly diagnosed with chronic Graft-versus-Host Disease (cGVHD). We want to see if this combination works better to manage the condition.
United States · Argentina · Australia